The reorganization of the US Food and Drug Administration's new drugs review program is proceeding into its second phase as the agency announced the acting leadership of three new offices within the Office of New Drugs.
"Some applications (e.g., INDs, NDAs, BLAs) may be affected during Phase II," the agency noted. "If there is a change...